-
Mashup Score: 1
SELECT-MDS-1 will be discontinued after failing to meet its primary end point of improved CR rates with tamibarotene/azacitidine in high-risk, RARA+ MDS.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia - 2 hour(s) ago
Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia #mpnsm #oncology https://t.co/LLD7HVjwQE
-
-
Mashup Score: 3Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers - 3 hour(s) ago
Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers @myESMO #ESMO24 #gynsm #ovca #oncology https://t.co/dExp7EVjQO
-
-
Mashup Score: 0
IBI354 favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
IBI354 Shows Efficacy and Safety in HER2+ and HER2-Low Advanced Breast Cancer @myESMO #ESMO2024 #bcsm #oncology https://t.co/F6l7gHDiDN
-
-
Mashup Score: 3
AstraZeneca has filed a new BLA for Dato-DXd in pretreated, EGFR-mutated advanced non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has received a new BLA seeking the accelerated approval of Dato-DXd for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR mutations who have received prior systemic therapies. #lcsm #oncology https://t.co/Sv3Bu7wZcq https://t.co/lNr9eLNi6O
-
-
Mashup Score: 0First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL - 7 hour(s) ago
First-line zanubrutinib generated a longer PFS in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma vs relapsed/refractory disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL @AjHematology #leusm #oncology https://t.co/8YEIGNjTbN
-
-
Mashup Score: 0
An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL #leusm #lymsm #medtwitter #oncology https://t.co/pROEbMPoXO
-
-
Mashup Score: 0Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation - 8 hour(s) ago
Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation #lcsm #medtwitter #oncology https://t.co/Vc7WQl1qXD
-
-
Mashup Score: 2ClinicalTrials.gov - 10 hour(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Oncologists1Tweet-
CLDN18.2 is another emerging target in #PancreaticCancer, highly expressed in ~20%. 2 trials to watch: ⚕️CLAUDIO-01: The CLDN18.2 ADC SOT102. https://t.co/l7jP7ORJ0b ⚕️TWINPEAK: Bi-specific Ab against CLDN18.2 + CD47. https://t.co/tywPYFd146 @SKamath_MD
-
-
Mashup Score: 0STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers - 10 hour(s) ago
Alberto Montero, MD, MBA, CPHQ, discusses the potential role for STX-478 in PIK3CA-mutant breast and gynecologic cancers.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers @UHhospitals @cwrusom #bcsm #gyncsm #oncology https://t.co/0bmrWbR43U
-
Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ #MDS https://t.co/oBBRXqU9cs